OMED OncoMed Pharmaceuticals, Inc.

-0.14  -4%
Previous Close 3.66
Open 3.70
Price To book 0.00
Market Cap 132.43M
Shares 37,623,000
Volume 1,727,859
Short Ratio 10.50
Av. Daily Volume 509,497

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 17, 2017 - primary endpoint not met.
Tarextumab - PINNACLE trial
Small cell lung cancer
Company announced late January 2016 that they plan to unblind the trial following notice from the DSMB that suggests a low likelihood of a statistically significant benefit in overall survival. Subsequently, in February 2016 an announcement was made to discontine the trial
Tarextumab ALPINE
Pancreatic Cancer

Latest News

  1. Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc.
  2. Edited Transcript of OMED earnings conference call or presentation 8-May-17 12:30pm GMT
  3. Human Antibody Discovery: Of Mice And Phage
  4. Strike three: Peninsula biotech swings, misses on third cancer drug trial in past month
  5. OncoMed Pharma stock drops 17% after clinical trial miss; Q1 revenue miss
  6. Investor Network: OncoMed Pharmaceuticals, Inc. to Host Earnings Call
  7. OncoMed reports 1Q loss
  8. OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results
  9. OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial
  10. OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017
  11. [$$] Four Small Biotechs See Bullish April Stock Buys
  12. Bay Area biotech slashes half of staff after drug partnerships falter
  13. OncoMed to lay off half of its staff
  14. OncoMed Announces Workforce Reduction
  15. Here's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today
  16. OncoMed is having a no good, very bad week
  17. OncoMed's lung cancer drug fails mid-stage study, shares tumble
  18. Biotech Movers: OncoMed, Incyte, Omeros
  19. OncoMed stock drops 25% after lung cancer drug misses in mid-stage clinical trial
  20. OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints